VANGUARD GROUP INC 13D and 13G filings for Intellia Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-01-08 11:29 am Purchase |
2024-12-31 | 13G | Intellia Therapeutics, Inc. NTLA |
VANGUARD GROUP INC | 10,189,953 10.000% |
1,842,504 (+22.07%) |
Filing |
| 2024-02-13 5:07 pm Purchase |
2023-12-29 | 13G | Intellia Therapeutics, Inc. NTLA |
VANGUARD GROUP INC | 8,347,449 9.320% |
537,223 (+6.88%) |
Filing |
| 2023-02-09 11:22 am Purchase |
2022-12-30 | 13G | Intellia Therapeutics, Inc. NTLA |
VANGUARD GROUP INC | 7,810,226 9.280% |
1,367,871 (+21.23%) |
Filing |
| 2022-02-10 08:17 am Purchase |
2021-12-31 | 13G | Intellia Therapeutics, Inc. NTLA |
VANGUARD GROUP INC | 6,442,355 8.660% |
1,311,158 (+25.55%) |
Filing |
| 2021-02-10 11:03 am Purchase |
2020-12-31 | 13G | Intellia Therapeutics, Inc. NTLA |
VANGUARD GROUP INC | 5,131,197 7.980% |
1,606,998 (+45.60%) |
Filing |